AP Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-422.75	-339.3	-288.54
Depreciation & Amortization	17.33	11.6	7.42
Other Amortization	0.16	0.98	1.25
Loss (Gain) From Sale of Assets	-	0	-
Stock-Based Compensation	55.69	24.74	29
Other Operating Activities	-2.92	0.79	-0.89
Change in Accounts Receivable	0.75	-2.31	-0.12
Change in Accounts Payable	5.78	14.58	-16.59
Change in Other Net Operating Assets	-11.91	-8.7	-7.51
Operating Cash Flow	-357.88	-297.62	-275.97
Capital Expenditures	-5.53	-35.03	-1.13
Sale (Purchase) of Intangibles	-	-0.38	-1.31
Investment in Securities	361.41	-430.7	-0.71
Other Investing Activities	-29.51	-2.56	-0
Investing Cash Flow	326.37	-468.68	-3.15
Long-Term Debt Repaid	-11.17	-3.11	-
Net Debt Issued (Repaid)	-11.17	-3.11	-
Issuance of Common Stock	1,207	-	800
Financing Cash Flow	1,196	-3.11	800
Foreign Exchange Rate Adjustments	-1.08	-	-
Net Cash Flow	1,163	-769.4	520.88
Free Cash Flow	-363.41	-332.65	-277.1
Free Cash Flow Margin	-	-1031.37%	-
Free Cash Flow Per Share	-4.83	-5.14	-5.26
Cash Interest Paid	1.54	1.13	-
Levered Free Cash Flow	-213.19	-211.61	-
Unlevered Free Cash Flow	-212.16	-210.86	-
Change in Net Working Capital	5.39	-4.41	-

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.